Literature DB >> 23541118

Trends in susceptibility of selected gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010.

Tim Babinchak1, Robert Badal, Daryl Hoban, Meredith Hackel, Stephen Hawser, Sibylle Lob, Samuel Bouchillon.   

Abstract

This report summarizes data from the Study for Monitoring Antimicrobial Resistance Trends 2005-2010 to identify trends in susceptibility from intra-abdominal infections in North America. Escherichia coli and Klebsiella pneumoniae were the most frequently isolated pathogens. Extended-spectrum beta-lactamase rates (%) in 2005/2010 for E. coli and K. pneumoniae were 1.7/7.3 and 3.2/13.1, respectively. Ertapenem, imipenem, amikacin, and cefoxitin showed stable susceptibility.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23541118     DOI： 10.1016/j.diagmicrobio.2013.02.031

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  14 in total

1.  Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Authors:  Christopher Lucasti; Ellie Hershberger; Benjamin Miller; Sara Yankelev; Judith Steenbergen; Ian Friedland; Joseph Solomkin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  The Rise of Fluoroquinolone-Resistant Escherichia coli in the Community: Scarier Than We Thought.

Authors:  Brad Spellberg; Yohei Doi
Journal:  J Infect Dis       Date:  2015-05-12       Impact factor: 5.226

Review 3.  Secondary peritonitis: principles of diagnosis and intervention.

Authors:  James T Ross; Michael A Matthay; Hobart W Harris
Journal:  BMJ       Date:  2018-06-18

Review 4.  Clinical importance and epidemiology of quinolone resistance.

Authors:  Eu Suk Kim; David C Hooper
Journal:  Infect Chemother       Date:  2014-12-29

5.  In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections.

Authors:  Gregory G Stone; Paul Newell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

6.  Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013.

Authors:  Sibylle H Lob; Krystyna M Kazmierczak; Robert E Badal; Meredith A Hackel; Samuel K Bouchillon; Douglas J Biedenbach; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

Review 7.  Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.

Authors:  Joshua T Thaden; Jason M Pogue; Keith S Kaye
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

Review 8.  Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.

Authors:  Stephanie E Giancola; Monica V Mahoney; Tiffany E Bias; Elizabeth B Hirsch
Journal:  Ther Clin Risk Manag       Date:  2016-05-19       Impact factor: 2.423

9.  A Review of Ten Years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011.

Authors:  Ian Morrissey; Meredith Hackel; Robert Badal; Sam Bouchillon; Stephen Hawser; Douglas Biedenbach
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-01

Review 10.  Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections.

Authors:  Kellie J Goodlet; David P Nicolau; Michael D Nailor
Journal:  Ther Clin Risk Manag       Date:  2016-12-01       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.